# Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS

> **NCT05879484** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Sinonasal Cancer
- Squamous Non-small Cell Lung Cancer
- Lung Cancer
- Head and Neck Squamous Cell Carcinoma
- Head and Neck Carcnimona
- Head and Neck Cancer

## Interventions

- **DRUG:** pembrolizumab
- **DRUG:** valemetostat

## Key facts

- **NCT ID:** NCT05879484
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-07-09
- **Primary completion:** 2025-07-09
- **Final completion:** 2025-07-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was never opened for enrollment as the CRADA was never executed
- **Last updated:** 2025-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05879484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05879484, "Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05879484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*